Epitope specificity of HLA class I alloantibodies .2. Stability of cross-reactive group antibody patterns over extended time periods
Epitope specificity of HLA class I alloantibodies .2. Stability of cross-reactive group antibody patterns over extended time periods
复制标题
DOI：
10.1097/00007890-199703270-00015
复制
发表时间：
1997-03-27
期刊：
影响因子：
6.2
通讯作者：
Fuller, TC
中科院分区：
文献类型：
--
作者：
Rodey, GE;Revels, K;Fuller, TC
HLA同种抗体的稳定性进行了研究，在128个抗体阳性，潜在的肾移植受者平均为期3年。使用抗人球蛋白补体依赖性细胞毒性技术进行抗体检测。在这项研究中，抗体的特异性被分类为针对私有表位或交叉反应组（CREG）表位簇。在94%的患者中发现了可定义的抗体，其中89.5%的可定义抗体对CREG簇具有特异性。抗体反应性的模式是稳定的，在大多数患者的评价，即使面板反应性抗体（PRA）的百分比往往表现出相当大的波动。在患者中鉴定的220种可定义的私人特异性或CREG簇特异性抗体中，近80%在整个观察期间持续存在。% PRA的波动是常见的，但通常不是由于获得新的HLA抗体。大多数波动可归因于同一CREG簇内特异性的可变检测，可能是由于技术变异或抗体亲合力或滴度或细胞组组成的变化。这项研究表明，抗体特异性的模式是非常稳定的，在这个患者群体中，即使PRA值波动。这项研究进一步表明，HLA抗体特异性分析是一个更有用的淋巴细胞毒性试验的临床参数比简单的报告% PRA时，确定潜在的捐助者为个别患者。
The stability of HLA alloantibodies was studied in 128 antibody-positive, potential kidney transplant recipients over an average period of 3 years. Antibody detection was performed using an anti-human globulin-complement-dependent cytotoxicity technique. In this study, the specificity of antibodies was categorized as against either private epitopes or cross-reactive group (CREG) epitope clusters. Definable antibodies were found in 94% of patients, and 89.5% of the definable antibodies had specificity for CREG clusters. Patterns of antibody reactivity were stable in most of the patients evaluated, even though the percentage of panel-reactive antibody (PRA) often demonstrated considerable fluctuations. Of the 220 definable private-specific or CREG cluster-specific antibodies identified in the patients, nearly 80% persisted throughout the observation period The fluctuations in % PRA were common, but usually were not due to the acquisition of new HLA antibodies. Most fluctuations were attributable to variable detection of specificities within the same CREG cluster, possibly due to technique variation or changes in antibody avidity or titer or in cell panel composition. This study demonstrates that patterns of antibody specificity are remarkably stable in this patient population, even though PRA values fluctuated. This study further suggests that HLA antibody specificity analysis is a more useful clinical parameter of lymphocytotoxicity testing than simple reporting of % PRA when identifying potential donors for individual patients.